{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=30", "query": { "condition": "Resolution", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 1356, "total_pages": 136, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T10:52:35.769Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01877694", "title": "Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacterial Conjunctivitis" ], "interventions": [ { "name": "Auriclosene Solution 0.3%", "type": "DRUG" }, { "name": "Auriclosene Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NovaBay Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 217, "start_date": "2013-06", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-05-28", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01877694" }, { "nct_id": "NCT01247883", "title": "A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-04634817", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 13, "start_date": "2010-10", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2011-02-02", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01247883" }, { "nct_id": "NCT01408056", "title": "Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infantile Hemangiomas" ], "interventions": [ { "name": "Timolol 0.5% Gel Forming Solution (GFS)", "type": "DRUG" }, { "name": "Mupirocin 2% Ointment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "8 Months", "sex": "ALL", "summary": "1 Month to 8 Months" }, "enrollment_count": 0, "start_date": "2011-02", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01408056" }, { "nct_id": "NCT02038803", "title": "Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "TOBIpodhaler", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-10-10", "completion_date": "2014-05-07", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038803" }, { "nct_id": "NCT05409235", "title": "Nesvategrast (OTT166) in Diabetic Retinopathy (DR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Retinopathy" ], "interventions": [ { "name": "OTT166", "type": "DRUG" }, { "name": "Vehicle control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OcuTerra Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2022-07-29", "completion_date": "2023-12-29", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 67, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05409235" }, { "nct_id": "NCT03751098", "title": "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mydriasis" ], "interventions": [ { "name": "Tropicamide/Phenylephrine ophthalmic solution (TR/PE)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eyenovia Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 76, "start_date": "2018-12-01", "completion_date": "2019-01-21", "has_results": true, "last_update_posted_date": "2022-03-18", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 2, "location_summary": "Austin, Texas • San Antonio, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03751098" }, { "nct_id": "NCT06131801", "title": "Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancy", "Leukemia", "Lymphoma", "Acute Lymphocytic Leukemia", "ALL", "Acute Myelogenous Leukemia", "AML", "Chronic Myelogenous Leukemia", "CML", "Myeloproliferative Neoplasm", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Burkitt Lymphoma", "T-cell Lymphoma", "B Cell Lymphoma", "Peripheral T Cell Lymphoma", "Cutaneous B-Cell Lymphoma" ], "interventions": [ { "name": "1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "38 Years", "sex": "ALL", "summary": "0 Years to 38 Years" }, "enrollment_count": 30, "start_date": "2023-11-15", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 6, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06131801" }, { "nct_id": "NCT07490535", "title": "This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ocular Surface Disease", "Dry Eye Syndrome (DES)" ], "interventions": [ { "name": "(Xiidra®) Lifitegrast Ophthalmic Solution 5.0%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pittsburgh Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-03", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 1, "location_summary": "Sewickley, Pennsylvania", "locations": [ { "city": "Sewickley", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07490535" }, { "nct_id": "NCT06063876", "title": "Experimental Peri-implant Mucositis on Implant Sites That Were Previously Treated With or Without Implantoplasty", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Peri-implant Mucositis", "Peri-Implantitis" ], "interventions": [ { "name": "Induction of experimental peri-implant mucositis", "type": "PROCEDURE" }, { "name": "Resolution of experimental peri-implant mucositis", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2023-09-05", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06063876" }, { "nct_id": "NCT02914613", "title": "Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "SF0166 Topical Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OcuTerra Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2016-08-24", "completion_date": "2017-05-16", "has_results": true, "last_update_posted_date": "2023-05-11", "last_synced_at": "2026-10-28T10:52:35.769Z", "location_count": 6, "location_summary": "Beverly Hills, California • Inglewood, California • Rancho Cordova, California + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Rancho Cordova", "state": "California" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02914613" } ] }